Epidemiological evidence supports a positive association between circulating insulin-like growth factor-1 (IGF-1) concentrations and breast cancer risk, but both the magnitude and causality of this relationship are uncertain. We conducted observational analyses with adjustment for regression dilution bias, and Mendelian randomization (MR) analyses to allow causal inference.
Introduction
Insulin-like growth factor-1 (IGF-1) is a polypeptide that has mitogenic and anti-apoptotic effects 1,2 . Approximately 99% of IGF-1 is bound to IGF binding proteins, with most bound to insulin-like growth factor-binding protein-3 (IGFBP-3) 3 . In experimental studies, IGFBP-3 has also been shown to not only regulate IGF-1 bioavailability, but also to have direct inhibitory effects on cell growth 4 .
Interest in the possible role of IGF-1 in the development of breast cancer began in the 1980s 5 . An early case-control study reported higher plasma concentrations of IGF-1 in women with breast cancer than in controls 6 , and in the first prospective study circulating concentrations of IGF-1 were positively associated with breast cancer risk for premenopausal women, but not postmenopausal women 7 . Most subsequent prospective studies have supported a positive association between IGF-1 and breast cancer risk, and a pooled individual-participant data analysis of 4,790 cases from 17 prospective studies showed that women with relatively high circulating IGF-1 had a ~30% higher risk of breast cancer than women with relatively low circulating IGF-1; there was no evidence that the association was due to reverse-causation, varied by menopausal status, or was attenuated by adjustment for other risk factors including IGFBP-3, reproductive factors, and body mass index (BMI) 8 . However, heterogeneity by estrogen receptor (ER) subtype was found, with the positive association present for ER + , but not ERtumours. In addition, this pooled analysis was based on a single IGF-1 measure for each woman so risk estimates would have been influenced by the combined effects of measurement error and within-person variability, leading to a likely underestimation of the true association (regression dilution) 8,9 . To further examine the possible causal role of IGF-1 in breast cancer risk, we conducted complementary observational and Mendelian randomization (MR) analyses. Firstly, we investigated how prediagnostic circulating concentrations of IGF-1 were related to breast cancer risk in the UK Biobank study, a large prospective cohort in which a subsample of participants have repeat IGF-1 measures enabling correction for regression dilution bias.
Next, we used a two-sample MR approach to examine potential causal associations by combining genetic variants associated with circulating IGF-1 and IGFBP-3 concentrations in genome-wide association studies (GWAS), and then assessing the association of these variants with breast cancer (overall, ER + , and ER -) risk in a large consortium of 122,977 breast cancer cases and 105,974 controls 10 .
Methods

UK Biobank -observational analysis
Study participants
The UK Biobank is a prospective cohort of 502,536 adults aged between 40 and 69 years (229,182 men and 273,474 women) who were recruited between 2006 and 2010 11 . The UK Biobank invited ~9.2 million people to participate through postal invitation with a telephone follow-up, with a response rate of 5.7%. All participants were registered with the UK National Health Service (NHS) and lived within ~25 miles (40 km) of one of the 22 study assessment centres. The UK Biobank has approval from the North West Multi-centre Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. In addition, an independent Ethics and Governance Council was formed in 2004 to oversee UK Biobank's continuous adherence to the Ethics and Governance Framework which was developed for the study (http://www.ukbiobank.ac.uk/ethics/). All participants provided written informed consent at recruitment and to be followed up using data-linkage. This research has been conducted using the UK Biobank Resource under application numbers 3248 and 24494.
During the baseline recruitment visit, participants were asked to complete a selfadministered touchscreen questionnaire, which included questions on socio-demographics (including age, sex, education and postcode, used to assign Townsend deprivation score), health/medical history, and lifestyle exposures (including smoking habits, dietary intakes, and alcohol consumption). At the baseline visit, participants also underwent physical measurements, including body weight, height, and waist circumference. Blood samples were collected from all participants at recruitment, and repeat blood samples were collected from a subset of ~20,000 participants who re-attended the assessment center between 2012 and 2013. Blood samples were centrifuged, and serum stored at -80°C.
Exclusions prior to the onset of analyses were men (N=229,134); women with prevalent cancer (including in situ breast cancer, but excluding non-malignant skin cancer) at recruitment (N=18,654); participants in whom genetic sex differed from reported gender (N=121), missing data on body size measurements (N=1,350); prevalent type-2 diabetes or unknown diabetes status at recruitment based on hospital records and self-report (because diabetes medications can affect circulating concentrations of IGF-1 12 ; N=10,705); women who reported oral contraceptive and menopausal hormone use at recruitment (because oral oestrogens alter hepatic protein production and change circulating concentrations of IGF-1 12 ; N=20,988); and participants without an IGF-1 measurement (N=15,415). Our analysis therefore included 206,263 women.
Blood collection and laboratory methods
As part of the UK Biobank Biomarker Project 13 , serum concentrations of IGF-1 (DiaSorin Liaison XL), estradiol, testosterone, and sex hormone binding globulin (SHBG) were determined by a chemiluminescent immunoassay (Beckman Coulter DXI 800). The Immunoturbidimetric method (Beckman Coulter DXI 800) was used to assay serum high sensitivity C-reactive protein (CRP) concentrations. Glycated haemoglobin (HbA1c) concentrations were determined using the HPLC Variant II Turbo 2.0 system (Bio-Rad). Full details on assay performance have been published 13 . In summary, average within-laboratory (total) coefficient of variation (CV) for low, medium, and high internal quality control level samples for each biomarker ranged from 1.7-15.3% (for IGF-1, the CVs ranged from 5.3-6.2%) 13 . A total of 6,711 women had IGF-1 concentrations measured in blood samples collected at both the recruitment and repeat assessment visit (median of 4-years apart).
Assessment of outcome
Incident cancer cases and cancer cases first recorded in death certificates within the UK Biobank cohort were identified through linkage to national cancer registries and death records. Complete follow-up was available until 31st March 2016 for England and Wales and 31st October 2015 for Scotland. Cancer incidence data were coded using the 10th Revision of the International Classification of Diseases (ICD-10). Breast cancer was defined as registration ICD-10: C50.
Statistical analysis
Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Age was the primary time variable in all models. Time at entry was age at recruitment. Exit time was age at whichever of the following came first: breast cancer diagnosis, breast cancer at death without prior diagnosis, death, or the last date at which follow-up was considered complete. Models were stratified by age at recruitment in 5year categories, Townsend deprivation index fifths, and region of the recruitment assessment centre. Deviations from proportionality were assessed using an analysis of Schoenfeld residuals, with no evidence of non-proportionality being detected. IGF-1 was modelled on the continuous scale (per 5 nmol/L) and with participants grouped into sexspecific fifths of circulating concentrations.
HRs were additionally corrected for regression dilution using regression dilution ratios obtained from the subsample of 6,711 women with repeated IGF-1 measurement 9, 14 ; to obtain corrected HRs the log HRs and their standard errors were divided by the regression dilution ratio for IGF-1 (0.74) and then exponentiated 15 . Possible nonlinear effects were modelled using restricted cubic spline models with five knots placed at Harrell's default percentiles of circulating IGF-1 concentrations 16 .
The multivariable model (model 1) was adjusted for a set of breast cancer risk factors determined a priori namely total physical activity, height, alcohol consumption frequency, smoking status and intensity, educational level, ever use of hormone replacement therapy (HRT), parity and age at first birth, and an interaction between menopausal status and BMI.
We also additionally adjusted the multivariable models (model 2) for markers of inflammatory, sex hormone, and glycemic pathways that are known to interrelate/crosstalk with the IGF system 12 , namely CRP, testosterone, SHBG, and HbA1c. Statistical tests for trend were calculated using the ordinal fifths of IGF-1 entered into the model as a continuous variable.
The circulating IGF-1 and breast cancer associations were further assessed across subgroups of BMI, height, menopausal status at recruitment, ages at blood collection and diagnosis, follow-up time, smoking status, and circulating concentrations of CRP, HbA1c, testosterone, and SHBG. Interaction terms (multiplicative scale) between these variables and circulating IGF-1 concentrations were included in separate models, and the statistical significance of the cross-product terms were evaluated using the likelihood ratio test, or competing risk for follow-up time and age at diagnosis.
Statistical tests were all two-sided and a Pvalue<0.05 was considered statistically significant.
Analyses were conducted using Stata version 14.
Mendelian randomization
Genetic determinants of insulin-like growth factor 1 (IGF-1) and insulin-like growth factorbinding protein-3 (IGFBP-3)
Genetic markers for circulating IGF-1 and IGFBP-3 concentrations comprised SNPs identified (Pvalue<5 x 10 -8 ) from the largest GWAS to date 17, 18 . For IGF-1, this GWAS was of 194,174 women from the UK Biobank 18 . The GWAS analyses of IGFBP-3 combined data on 18,995 individuals (men and women) from 13 studies 17 . All participants were of European ancestry. From the genome-wide significant variants identified in these GWAS, we excluded correlated SNPs based on a linkage disequilibrium (LD) level of R 2 <0.01. The instruments for IGF-1 (265 SNPs) and IGFBP-3 (4 SNPs) explained 5.2% and 6.1% of variability in circulating concentrations, respectively. Summary information on the genetic instruments, and the effect estimates for each individual SNP with IGF-1 and IGFBP-3 concentrations, are presented in Tables S1 and S2.
Data on breast cancer
Summary data for the associations of the IGF-1 and IGFBP-3 related genetic variants with breast cancer were obtained from a GWAS of 228,951 women (122,977 breast cancer [69,501 ER + , 21,468 ER -] cases and 105,974 controls) of European ancestry from the Breast Cancer Association Consortium (BCAC) 10 . Genotypes were imputed using the 1000 Genomes Project reference panel and the regression models adjusted for the first ten principal components and country or study. Effect estimates for the association of each individual SNP with breast cancer are presented in Table S2 .
Statistical analysis
Two-sample MR analyses using summary data and an inverse variance weighted approach were implemented. MR results correspond to an odds ratio (OR) per 5 nmol/L of genetically- and breast cancer association, we used an MR-Egger regression approach 19 . We also computed OR estimates using the complementary weighted-median method that can give valid MR estimates under the presence of pleiotropy when up to 50% of the included instruments are invalid 20 . The presence of pleiotropy was also assessed using the MR pleiotropy residual sum and outlier test (MR-PRESSO). In this, outlying SNPs are excluded from the instruments and the effect estimates are reassessed 21 . As a visual evaluation of directional pleiotropy (asymmetry), we also examined a funnel plot of the effect estimate and standard error of each SNP within the IGF-1 instrument on breast cancer risk. For the IGFBP-3 instrument, we conducted leave-one-out analyses to assess the influence of individual variants on the observed associations. All statistical analyses were performed using the MendelianRandomization R package 22 .
Results
UK Biobank -observational analysis
After a median follow-up time of 7.1 years, 4,360 incident breast cancer cases were recorded. Compared to those in the lowest fifth, participants in the highest circulating IGF-1 fifth were younger, taller, had lower BMI and waist circumference, and were more likely to be never smokers, nulliparous, and never HRT users (Table 1 ). In addition, participants in the highest circulating IGF-1 fifth had lower circulating concentrations of CRP, HbA1c, and SHBG, with higher circulating concentrations of testosterone.
Association between circulating insulin-like growth factor 1 (IGF-1) concentrations and breast cancer risk
Circulating IGF-1 concentrations were positively associated with breast cancer risk in the minimally adjusted model (HR for highest versus lowest fifth=1.23, 95%CI=1.12-1.36;
Ptrend<0.0001) ( Table S3 ).
Mendelian randomization
Association between genetically-predicted circulating insulin-like growth factor 1 (IGF-1)
concentrations and breast cancer risk
In the inverse-variance weighted model, a 5 nmol/L increment in genetically-predicted IGF-1 concentrations was associated with greater breast cancer risk (OR=1.05, 95%CI=1.01-1.10;
Pvalue=0.02) ( Table 3) . A similar pattern of results was found when the MR-PRESSO test detected outlier SNPs were excluded from the models (Table S4 ). The funnel plots for the
Association between genetically-predicted circulating insulin-like growth factor-binding protein-3 (IGFBP-3) concentrations and breast cancer risk
No association was found between genetically-predicted circulating IGFBP-3 concentrations and breast cancer risk (Table 3) . A similar null result was found for the weighted median, MR-Egger, and leave-one-out sensitivity analyses ( Table 3 , Table S5 ).
Discussion
In the observational analyses of UK Biobank data, we found that higher circulating 8 and laboratory evidence 28 , which suggests that crosstalk from estrogen signaling pathways may influence the IGF-1 and breast cancer relationship.
The bioavailability of IGF-1 in circulation is partly regulated by IGFBPs, with most bound to IGFBP-3. In addition to enhancing or inhibiting actions of IGF ligands, in vitro experimental models suggest that IGFBP-3 can inhibit breast cancer proliferation and induce apoptosis 4, 29 .
Our MR analyses found no evidence of an association between genetically-predicted IGFBP-3 concentrations and breast cancer risk. This result is consistent with the Endogenous Hormones and Breast Cancer Collaborative Group analysis that reported a null association for IGFBP-3 concentrations and breast cancer risk after the multivariable models were adjusted for circulating IGF-1 concentrations 8 . Taken together, these results provide little evidence of IGFBP-3 having a direct effect, independent of its role in IGF ligand binding, in breast cancer development.
A fundamental assumption of MR analyses is that the genetic instrument should not influence the outcome via a different biological pathway from the exposure of interest (horizontal pleiotropy). We conducted various sensitivity analyses to assess the possible influence of horizontal pleiotropy on our causal estimates, and our results were robust to these various tests. The possibility exists, however, that our results may have been influenced by pleiotropy from other unmeasured IGF axis components 30 . To date, the only GWAS analyses that have been conducted for components of this pathway are for IGF-1 and IGFBP-3, therefore the extent of this possible pleiotropy within the IGF axis is uncertain.
Genetic instruments are now required for other IGF system components to disentangle possible biological effects of specific ligands and binding proteins in breast cancer development.
The current study is the largest and most comprehensive investigation of the role of IGF-1 in breast cancer development. A limitation of our observational analysis is that tumor subtype data are currently unavailable in the UK Biobank; however, these data were available for our MR analyses and we found that the positive effect for IGF-1 and breast cancer was only present for ER + tumors. For our MR analyses, we were unable to stratify the analyses by menopausal status; however, our observational analyses found no difference in the IGF-1 and breast cancer relationship between pre-and post-menopausal women. Our use of summary-level data for our MR analyses meant that we were unable to examine possible non-linear effects or whether the associations between IGF-1 and breast cancer differed according to subgroups of other risk factors (e.g. BMI, alcohol consumption); however, in our observational analyses, which yielded a similar association to our MR result, we found a linear association between IGF-1 and breast cancer and detected no heterogeneity by subgroups of other risk factors.
In conclusion, given that plausible biological mechanisms have been identified 1,2 , our observational and MR results support a probable causal relationship between circulating IGF-1 concentrations and breast cancer. This result suggests that pharmacological or lifestyle interventions targeting the IGF pathway may be beneficial in preventing breast tumorigenesis. HR=hazard ratio; CI=confidence interval. Multivariable Cox regression model using age as the underlying time variable and stratified by Townsend deprivation index (fifths), region of the recruitment assessment center, and age at recruitment (5-year categories). Models adjusted for total physical activity (<10, 10-<20, 20-<40, 40-<60, ≥ 60 MET hours per week, unknown); height (per 10 cm); alcohol consumption frequency (never, special occasions only, 1-3 times per month, 1-2 times per week, 3-4 times per week, daily/almost daily, unknown); smoking status and intensity (never, former, current-<15 per day, current-≥ 15 per day, current-intensity unknown, unknown); educational level (CSEs/O-levels/GCSEs or equivalent, NVQ/HND/HNC/A-levels/AS-levels or equivalent, other professional qualifications, college/university degree, none of the above, unknown); ever use of hormone replacement therapy (no, yes, unknown); parity, age at first birth (nulliparous; 1-2, <25 years; 1-2, 25-30 years; 1-2, 
